Palmieri G, Montella L, Lastoria S
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, Naples, Italy.
Minerva Endocrinol. 2001 Sep;26(3):193-5.
Thymic tumours are rare neoplasms which generally follow a slow pattern of growth, showing their aggressiveness locally through the infiltration of adjacent organs and they rarely metastasise hematogenically. In the presence of locally advanced, metastatic or inoperable disease, combined strategies including chemotherapy, radiotherapy and surgery are now being evaluated. Scintigraphy with 111In DTPA-D-Phe 1 octreotide was used for the first time in a relevant series of patients with thymic tumour (13 cases) by our research group. The presence of somatostatin receptors (ss-R) assayed in vivo provided the rationale for the use of a treatment based on the octreotide analog in a patient with thymoma and aplasia of the erythroid series (pure red cell aplasia, PRCA) in whom a complete response for the tumour and the remission of anemia was obtained. The efficacy of this treatment was confirmed by our series of patients with chemoresistant thymic tumour and by national and international confirmations. These data, ranging from in vivo diagnosis to treatment and the in vitro study of receptor expression, confirm that somatostatin plays a major role in thymic tumours.
胸腺瘤是一种罕见的肿瘤，通常生长缓慢，通过浸润邻近器官在局部表现出侵袭性，很少发生血行转移。对于局部晚期、转移性或无法手术的疾病，目前正在评估包括化疗、放疗和手术在内的联合治疗策略。我们研究小组首次在一系列相关的胸腺瘤患者（13例）中使用111In DTPA-D-Phe 1奥曲肽进行闪烁扫描。体内检测到的生长抑素受体（ss-R）为在一名患有胸腺瘤和红系发育不全（纯红细胞再生障碍，PRCA）的患者中使用基于奥曲肽类似物的治疗提供了理论依据，该患者的肿瘤获得了完全缓解，贫血也得到了缓解。我们的化疗耐药胸腺瘤患者系列以及国内和国际的证实均证实了这种治疗的有效性。这些数据，从体内诊断到治疗以及受体表达的体外研究，证实生长抑素在胸腺瘤中起主要作用。
